AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27553723 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study 25237463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg (group A)
Number of subjects: 187
Study 25237463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg and solifenacin 5 mg (group B)
Number of subjects: 187
Study 22169359 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 221
Study 22169359 — intervention group
Group type: COMPARATOR
Intervention: Streitberger placebo acupuncture
Number of subjects: 221
Study 22169359 — intervention group
Group type: COMPARATOR
Intervention: Mock electrical stimulation
Number of subjects: 221
Study 22169359 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic consultations
Number of subjects: 221
Study 22169359 — intervention group
Group type: EXPERIMENTAL
Intervention: Practitioner 3
Number of subjects: 221
Study 19508590 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine (ACh) infusion
Number of subjects: 32
Study 19508590 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (NP) infusion
Number of subjects: 32
Study 19508590 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE) infusion
Number of subjects: 32
Study 19508590 — intervention group
Group type: COMPARATOR
Intervention: Serum C‐reactive protein (CRP) measurement
Number of subjects: 32
Study 19508590 — intervention group
Group type: COMPARATOR
Intervention: Serum TNF‐alpha measurement
Number of subjects: 32
Study 19508590 — intervention group
Group type: COMPARATOR
Intervention: Serum asymmetric dimethylarginine (ADMA) measurement
Number of subjects: 32
Study 19508590 — intervention group
Group type: COMPARATOR
Intervention: Forearm balance of nitric oxide (NO) during ACh infusion
Number of subjects: 32
Study 18229580 — intervention group
Group type: EXPERIMENTAL
Intervention: Xueshuantong (Panax notoginseng saponins)
Number of subjects: 62
Study 18229580 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid and Xueshuantong
Number of subjects: 62
Study 18229580 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid, DF‐521 and Xueshuantong
Number of subjects: 62
Study 15715181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised sidenadet (3mg tid; n = 7)
Number of subjects: 15
Study 15715181 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (5mg tid; n = 8)
Number of subjects: 15
Study 11889308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 24
Study 11889308 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 24
Study 11889308 — intervention group
Group type: COMPARATOR
Intervention: Control (non-septic patients)
Number of subjects: 24
Study 11889308 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 24
Study 9817627 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine and pindolol
Number of subjects: 15
Study 9817627 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine and placebo
Number of subjects: 15
Study 8765697 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin hard-gelatin capsule with saturated polyglycolysed glycerides (Gelucire)
Number of subjects: 6
Study 8765697 — intervention group
Group type: COMPARATOR
Intervention: Standard multiple-unit diffusion-controlled pellet capsule (reference formulation)
Number of subjects: 6
Study 2501987 — intervention group
Group type: EXPERIMENTAL
Intervention: 123IMP-SPECT
Number of subjects: 49
Study 2501987 — intervention group
Group type: COMPARATOR
Intervention: CT scans
Number of subjects: 49
Study 2501987 — intervention group
Group type: COMPARATOR
Intervention: IV contrast-enhanced CT
Number of subjects: 49
Study 2501987 — intervention group
Group type: EXPERIMENTAL
Intervention: 123IMP-SPECT and CT scans
Number of subjects: 49
Study 173814 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone (22 patients)
Number of subjects: 63
Study 173814 — intervention group
Group type: COMPARATOR
Intervention: 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) orally at intervals of 8 weeks (22 patients)
Number of subjects: 63
Study 173814 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiation and drug therapy (19 patients)
Number of subjects: 63
Study 31770006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Boolean models of cellular circuits
Number of subjects: 0
Study 31770006 — intervention group
Group type: COMPARATOR
Intervention: Randomized models
Number of subjects: 0
Study 27609785 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 G vitrectomy plus encircling band (group E1)
Number of subjects: 257
Study 27609785 — intervention group
Group type: COMPARATOR
Intervention: 20 G vitrectomy without any buckle (group C)
Number of subjects: 257
Study 27609785 — intervention group
Group type: EXPERIMENTAL
Intervention: 23/25 G vitrectomy without any buckle (group E2)
Number of subjects: 257
Study 27609785 — intervention group
Group type: EXPERIMENTAL
Intervention: Best corrected visual acuity
Number of subjects: 257
Study 27609785 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical refraction shift
Number of subjects: 257
Study 27609785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative complications
Number of subjects: 257
Study 27609785 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 257
Study 26117437 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cerebellar continuous theta burst stimulation (cTBS)
Number of subjects: 13
Study 26117437 — intervention group
Group type: COMPARATOR
Intervention: Sham cerebellar continuous theta burst stimulation (cTBS)
Number of subjects: 13
Study 23186806 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 23186806 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin in patients without HF
Number of subjects: 0
Study 23186806 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin in patients with HF
Number of subjects: 0
Study 21764498 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation training (HFST)
Number of subjects: 93
Study 21764498 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (TT)
Number of subjects: 93
Study 19350245 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular obstruction (MO)
Number of subjects: 184
Study 19350245 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent microvascular obstruction (PMO)
Number of subjects: 184
Study 19350245 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Registry of Acute Coronary Events (GRACE) risk score
Number of subjects: 184
Study 19350245 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct size (IS) greater than 10%
Number of subjects: 184
Study 19350245 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction less than 40%
Number of subjects: 184
Study 16805893 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) during hemodialysis
Number of subjects: 0
Study 16805893 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15006955 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF), 400 mg
Number of subjects: 47
Study 15006955 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (LEVO), 500 mg daily for five doses
Number of subjects: 47
Study 15006955 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZI), 500 mg for one dose, then 250 mg daily for four doses
Number of subjects: 47
Study 10844047 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel intraocular lenses
Number of subjects: 93
Study 10844047 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate intraocular lenses
Number of subjects: 93
Study 10844047 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intraocular lenses
Number of subjects: 93
Study 10844047 — intervention group
Group type: COMPARATOR
Intervention: Comparison of visual acuity
Number of subjects: 93
Study 10844047 — intervention group
Group type: COMPARATOR
Intervention: Comparison of contrast sensitivity
Number of subjects: 93
Study 9113618 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 96
Study 9113618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 8240608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabbage leaves application
Number of subjects: 120
Study 8240608 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 120
Study 3707653 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 14
Study 3707653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3707653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 50 mg t.i.d.
Number of subjects: 14
Study 3358887 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin 1 g
Number of subjects: 14
Study 3358887 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin 2 g
Number of subjects: 14
Study 3358887 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin 4 g
Number of subjects: 14
Study 3358887 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin 2 g daily for 6 weeks
Number of subjects: 14
Study 3358887 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin 3 g daily for 6 weeks
Number of subjects: 14
Study 3358887 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment (1 week after stopping vigabatrin)
Number of subjects: 14
Study 31619191 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of partners on attitudes toward child feeding
Number of subjects: 307
Study 31619191 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of partners on attitudes toward physical activity
Number of subjects: 307
Study 31619191 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of partners on attitudes toward television viewing
Number of subjects: 307
Study 31619191 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of partners on breastfeeding duration
Number of subjects: 307
Study 31619191 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of social connections on attitudes
Number of subjects: 307
Study 31619191 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of peers and family on attitudes
Number of subjects: 307
Study 28488137 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 26
Study 28488137 — intervention group
Group type: COMPARATOR
Intervention: CONT
Number of subjects: 26
Study 25726984 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-focused intervention (WFI)
Number of subjects: 431
Study 25726984 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 431
Study 23253948 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin 50 mg q.d. for 5 days with metformin 1,000 mg b.i.d. for 3 days and 1,000 mg q.d. on Day 4
Number of subjects: 16
Study 23253948 — intervention group
Group type: COMPARATOR
Intervention: metformin 1,000 mg b.i.d. for 3 days and 1,000 mg q.d. on Day 4
Number of subjects: 16
Study 21727662 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (75 mg/day for 12 weeks)
Number of subjects: 43
Study 21727662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 18371182 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV‐plus‐RT
Number of subjects: 247
Study 18371182 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 247
Study 18371182 — intervention group
Group type: EXPERIMENTAL
Intervention: CFO
Number of subjects: 247
Study 18371182 — intervention group
Group type: EXPERIMENTAL
Intervention: NCFO
Number of subjects: 247
Study 16490805 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg aprepitant capsule on day 1 followed by 80 mg on days 2 and 3
Number of subjects: 0
Study 16490805 — intervention group
Group type: COMPARATOR
Intervention: 125 mg and 80 mg aprepitant capsules administered in fed vs. fasted state
Number of subjects: 0
Study 16490805 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day regimen of aprepitant (125 mg/80 mg/80 mg)
Number of subjects: 0
Study 12721261 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 0
Study 12721261 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 0
Study 12721261 — intervention group
Group type: COMPARATOR
Intervention: No endocrine therapy
Number of subjects: 0
Study 12721261 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (Cyclophosphamide, Methotrexate, and Fluorouracil)
Number of subjects: 0
Study 12721261 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine treatment (Goserelin or Tamoxifen)
Number of subjects: 0
Study 10714571 — intervention group
Group type: EXPERIMENTAL
Intervention: COL-1492 (52.5 mg N-9 gel)
Number of subjects: 0
Study 10714571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9373488 — intervention group
Group type: EXPERIMENTAL
Intervention: ETDRS method
Number of subjects: 70
Study 9373488 — intervention group
Group type: EXPERIMENTAL
Intervention: Probit method
Number of subjects: 70
Study 9373488 — intervention group
Group type: COMPARATOR
Intervention: Line assignment method
Number of subjects: 70
Study 1303479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (1 gm per dose for 24 hours)
Number of subjects: 222
Study 1303479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (500 mg per dose for 24 hours)
Number of subjects: 222
Study 1303479 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 222
Study 3919746 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of lysine acetyl salicylate (LAS)
Number of subjects: 0
Study 3919746 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of morphine
Number of subjects: 0
Study 30850876 — intervention group
Group type: EXPERIMENTAL
Intervention: HELIOX with 25% helium in oxygen
Number of subjects: 44
Study 30850876 — intervention group
Group type: EXPERIMENTAL
Intervention: HELIOX with 50% helium in oxygen
Number of subjects: 44
Study 30850876 — intervention group
Group type: EXPERIMENTAL
Intervention: HELIOX with 75% helium in oxygen
Number of subjects: 44
Study 30850876 — intervention group
Group type: COMPARATOR
Intervention: Medical air (control)
Number of subjects: 44
Study 30571406 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 500
Study 30571406 — intervention group
Group type: COMPARATOR
Intervention: No endovascular treatment (non-EVT)
Number of subjects: 500
Study 30571406 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAC volume
Number of subjects: 500
Study 26685004 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab (100 mg, n = 9)
Number of subjects: 21
Study 26685004 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 8)
Number of subjects: 21
Study 23218458 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaping Up My Choices (SMC) programme, a 10-week school-based nutrition education curriculum
Number of subjects: 938
Study 23218458 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaping Up My Choices (SMC) programme
Number of subjects: 938
Study 22647518 — intervention group
Group type: EXPERIMENTAL
Intervention: Elinogrel (IV 80 or 120 mg followed by oral 50, 100, or 150 mg twice daily)
Number of subjects: 652
Study 22647518 — intervention group
Group type: EXPERIMENTAL
Intervention: Elinogrel
Number of subjects: 652
Study 22647518 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300 or 600 mg pre-procedure followed by 75 mg daily)
Number of subjects: 652
Study 19712541 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Aphasic Depression Questionnaire (SADQ H10)
Number of subjects: 125
Study 19712541 — intervention group
Group type: COMPARATOR
Intervention: Brief Assessment Schedule Depression Cards (BASDEC)
Number of subjects: 125
Study 18243641 — intervention group
Group type: EXPERIMENTAL
Intervention: General cancer-related educational material plus specific information about the efficacy of ondansetron
Number of subjects: 358
Study 18243641 — intervention group
Group type: COMPARATOR
Intervention: General cancer-related educational material
Number of subjects: 358
Study 15916717 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (0 or 30 mg sustained release each evening prior to testing, plus 0 or 15 mg immediate release each morning 2 hours before cocaine infusion)
Number of subjects: 12
Study 15916717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (0, 0.325, and 0.650 mg/kg)
Number of subjects: 12
Study 15916717 — intervention group
Group type: COMPARATOR
Intervention: Cocaine (with and without isradipine)
Number of subjects: 12
Study 12666694 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylscopolamine
Number of subjects: 20
Study 12666694 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 20
Study 12666694 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study 12666694 — intervention group
Group type: COMPARATOR
Intervention: ERCP without butylscopolamine or glucagon
Number of subjects: 20
Study 10464850 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid
Number of subjects: 66
Study 10464850 — intervention group
Group type: COMPARATOR
Intervention: Capsaicin
Number of subjects: 66
Study 7832349 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and buffered lidocaine (n = 25)
Number of subjects: 107
Study 7832349 — intervention group
Group type: COMPARATOR
Intervention: Placebo and buffered lidocaine (n = 27)
Number of subjects: 107
Study 7832349 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and plain lidocaine (n = 32)
Number of subjects: 107
Study 7832349 — intervention group
Group type: COMPARATOR
Intervention: Placebo and plain lidocaine (n = 23)
Number of subjects: 107
Study 1976875 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/day
Number of subjects: 796
Study 1976875 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and intravenous heparin
Number of subjects: 796
Study 1976875 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin
Number of subjects: 796
Study 230927 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate (2 g/day)
Number of subjects: 13
Study 230927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 28409515 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching condition
Number of subjects: 35
Study 28409515 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study 27451450 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum strain Bb (approximately one billion live cells daily for 4 weeks)
Number of subjects: 0
Study 27451450 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 24639432 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 µg once daily
Number of subjects: 391
Study 24639432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 22335622 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Ki67 index
Number of subjects: 128
Study 22335622 — intervention group
Group type: EXPERIMENTAL
Intervention: High Ki67 index
Number of subjects: 128
Study 22335622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki67 index (univariable analysis)
Number of subjects: 128
Study 22335622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki67 index (multivariable analysis)
Number of subjects: 128
Study 20823393 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive cilostazol 100 mg twice daily (triple group; n=69)
Number of subjects: 134
Study 20823393 — intervention group
Group type: COMPARATOR
Intervention: High maintenance-dose clopidogrel 150 mg daily (high-MD group; n=65)
Number of subjects: 134
Study 17372807 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive workshop (group I)
Number of subjects: 200
Study 17372807 — intervention group
Group type: COMPARATOR
Intervention: Printed instruction material (group II)
Number of subjects: 200
Study 17372807 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group I and group II
Number of subjects: 200
Study 15704507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 103
Study 12044509 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 570
Study 12044509 — intervention group
Group type: COMPARATOR
Intervention: Chondroblastic subtype
Number of subjects: 570
Study 10021951 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with 100 mg lidocaine 5% with 7.5% dextrose
Number of subjects: 10
Study 10021951 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with 600 mg lidocaine 2%
Number of subjects: 10
Study 7850821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (CLZ) 5 mg plus Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 1162
Study 7850821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1162
Study 7850821 — intervention group
Group type: COMPARATOR
Intervention: Cilazapril (CLZ) monotherapy
Number of subjects: 1162
Study 7850821 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) monotherapy
Number of subjects: 1162
Study 7850821 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg or 25 mg
Number of subjects: 1162
Study 2903182 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (≤30 mg/day)
Number of subjects: 3
Study 2903182 — intervention group
Group type: COMPARATOR
Intervention: Double-blind, randomized, crossover single case study
Number of subjects: 3
Study 2903182 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine withdrawal syndrome
Number of subjects: 3
Study 30428862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM) treatment for 6 months
Number of subjects: 242
Study 28232118 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline via Turbuhaler® M2
Number of subjects: 60
Study 28232118 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg terbutaline via Turbuhaler® M2
Number of subjects: 60
Study 28232118 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline via Turbuhaler® M3
Number of subjects: 60
Study 28232118 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg terbutaline via Turbuhaler® M3
Number of subjects: 60